Lympharma is developing novel Lymphatropic™ molecules - oral small molecules with intrinsic and preferential lymphatic absorption.

Existing small molecules can be transformed into lymphatropic molecules by chemically attaching a Lymphatic Guide - a small molecule enabling lymphatic absorption.

Advantages of Lymphatropic molecules include improved PK and improved tolerability.